These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 28644036)
1. Examining the Effect of Residual Amikacin on Sputum Culture for Nontuberculous Mycobacteria. Eagle G; Brown K; Floto RA Am J Respir Crit Care Med; 2018 Jan; 197(2):267-269. PubMed ID: 28644036 [No Abstract] [Full Text] [Related]
2. Postantibiotic effects of amikacin and ofloxacin on Mycobacterium fortuitum. Tsui SY; Yew WW; Li MS; Chan CY; Cheng AF Antimicrob Agents Chemother; 1993 May; 37(5):1001-3. PubMed ID: 8517688 [TBL] [Abstract][Full Text] [Related]
3. Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Olivier KN; Griffith DE; Eagle G; McGinnis JP; Micioni L; Liu K; Daley CL; Winthrop KL; Ruoss S; Addrizzo-Harris DJ; Flume PA; Dorgan D; Salathe M; Brown-Elliott BA; Gupta R; Wallace RJ Am J Respir Crit Care Med; 2017 Mar; 195(6):814-823. PubMed ID: 27748623 [TBL] [Abstract][Full Text] [Related]
4. Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection. Rose SJ; Neville ME; Gupta R; Bermudez LE PLoS One; 2014; 9(9):e108703. PubMed ID: 25264757 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Mycobacterial Growth Indicator Tube with Culture on RGM Selective Agar for Detection of Mycobacteria in Sputum Samples from Patients with Cystic Fibrosis. Eltringham I; Pickering J; Gough H; Preece CL; Perry JD J Clin Microbiol; 2016 Aug; 54(8):2047-50. PubMed ID: 27225412 [TBL] [Abstract][Full Text] [Related]
11. Clinical significance of a single isolation of pathogenic nontuberculous mycobacteria from sputum specimens. Koh WJ; Chang B; Ko Y; Jeong BH; Hong G; Park HY; Jeon K; Lee NY Diagn Microbiol Infect Dis; 2013 Feb; 75(2):225-6. PubMed ID: 23140755 [TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series. Namkoong H; Morimoto K; Nishimura T; Tanaka H; Sugiura H; Yamada Y; Kurosaki A; Asakura T; Suzuki S; Fujiwara H; Yagi K; Ishii M; Tasaka S; Betsuyaku T; Hoshino Y; Kurashima A; Hasegawa N BMC Infect Dis; 2016 Aug; 16():396. PubMed ID: 27506679 [TBL] [Abstract][Full Text] [Related]
13. Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease. Koh WJ; Jeong BH; Jeon K; Kim SY; Park KU; Park HY; Huh HJ; Ki CS; Lee NY; Lee SH; Kim CK; Daley CL; Shin SJ; Kim H; Kwon OJ Chest; 2016 Dec; 150(6):1211-1221. PubMed ID: 27167209 [TBL] [Abstract][Full Text] [Related]
14. Bronchial wash culture is less valuable in patients suspected to have nontuberculous mycobacteria lung disease for bilateral bronchiectasis with nodules. Watanabe K; Shinkai M; Shinoda M; Kaneko T Int J Mycobacteriol; 2018; 7(2):178-182. PubMed ID: 29900897 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Various Culture Media for Detection of Rapidly Growing Mycobacteria from Patients with Cystic Fibrosis. Preece CL; Wichelhaus TA; Perry A; Jones AL; Cummings SP; Perry JD; Hogardt M J Clin Microbiol; 2016 Jul; 54(7):1797-1803. PubMed ID: 27098962 [TBL] [Abstract][Full Text] [Related]
16. Outcomes of hypertonic saline inhalation as a treatment modality in nontuberculous mycobacterial pulmonary disease. Huiberts A; Zweijpfenning SMH; Pennings LJ; Boeree MJ; van Ingen J; Magis-Escurra C; Hoefsloot W Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31000680 [No Abstract] [Full Text] [Related]
17. Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection. Murray MP; Laurenson IF; Hill AT Clin Infect Dis; 2008 Jul; 47(2):222-4. PubMed ID: 18532890 [TBL] [Abstract][Full Text] [Related]